Search

Search Constraints

You searched for: Author/Creator Martinez, Felipe A.

Search Results

1. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). (21st March 2019)

2. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF. (24th November 2021)

3. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. (27th August 2022)

4. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Issue 20 (18th May 2021)

5. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. (7th November 2022)

6. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF. (6th February 2022)

7. Effect of dapagliflozin on anaemia in DAPA‐HF. (22nd March 2021)

8. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Issue 17 (27th October 2020)

9. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF. (18th January 2021)

10. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial. (10th March 2021)